---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005649"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T05:06:40.307949+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech reports positive Phase 2 topline results for Ampligen in post-COVID fatigue

## Summary
- Primary endpoint (PROMIS Fatigue Score at week 13) not significant; Ampligen showed lower fatigue at multiple timepoints vs placebo.
- Secondary and ad hoc analyses showed differences in PROMIS Fatigue Score reaching or approaching statistical significance at several timepoints.
- Six-Minute Walk Test: Ampligen group had higher distance traveled at week 13 vs placebo.
- Safety: Ampligen generally well tolerated; no severe TEAEs or deaths. 15% mild treatment-related TEAEs in Ampligen group.
- Study enrolled 80 subjects (40 per arm); 82.5% completed (90% Ampligen, 75% placebo).

## SEC filing metadata
- accession: 0001493152-24-005649
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315224005649/0001493152-24-005649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315224005649/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005649
- JSON: https://secwatch.observer/filing/0001493152-24-005649.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.